Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Glenmark Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Glenmark Pharmaceuticals şirketinin toplam hissedar öz sermayesi ₹78.5B ve toplam borcu ₹12.3B olup, bu da borç-öz sermaye oranını 15.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹143.6B ve ₹65.1B dir. Glenmark Pharmaceuticals 'in FAVÖK'ü ₹16.3B faiz karşılama oranı 3.7 dur. Şirketin ₹16.6B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
15.7%
Borç/özkaynak oranı
₹12.31b
Borç
| Faiz karşılama oranı | 3.7x |
| Nakit | ₹16.59b |
| Eşitlik | ₹78.48b |
| Toplam yükümlülükler | ₹65.11b |
| Toplam varlıklar | ₹143.59b |
Son finansal sağlık güncellemeleri
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20Recent updates
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: GLENMARK 'nin kısa vadeli varlıkları ( ₹74.3B ) kısa vadeli yükümlülüklerini ( ₹58.2B ) aşıyor.
Uzun Vadeli Yükümlülükler: GLENMARK şirketinin kısa vadeli varlıkları ( ₹74.3B ) uzun vadeli yükümlülüklerini ( ₹6.9B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: GLENMARK şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: GLENMARK 'nin borç/öz sermaye oranı son 5 yılda 64.7% seviyesinden 15.7% seviyesine düştü.
Borç Kapsamı: GLENMARK 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.
Faiz Kapsamı: GLENMARK 'in borcuna ilişkin faiz ödemeleri EBIT ( 3.7 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.